Pharmacokinetic analysis and phase 1 study of MRX-1024 in patients treated with radiation therapy with or without cisplatinum for head and neck cancer

Clinical Cancer Research

Volumn 16, Issue 9, 2010, Pages 2666-2676

  Hamstra, Daniel A ^a   Eisbruch, Avraham ^a   Naidu, Maddireddy U R ^d   Ramana, Gogula V ^e   Sunkara, Prasad ^c   Campbell, Kathleen C M ^f   Ross, Brian D ^b,c   Rehemtulla, Alnawaz ^a,c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c Molecular Therapeutics Inc   (United States)

^d NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

^e NATCO   (India)

^f SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METHIONINE; MRX 1024; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEVER; HEAD AND NECK CANCER; HUMAN; INCIDENCE; LYMPHOCYTOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; METABOLIC CLEARANCE RATE; METHIONINE; MIDDLE AGED; MUCOSITIS; NAUSEA; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; STEREOISOMERISM; STOMATITIS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 77951759644     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-3318     Document Type: Article

References (46)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Sonis ST, Peterson DE, McGuire DB, Williams DA. Prevention of mucositis in cancer patients. J Natl Cancer Inst 2001:1-2.
3. Shih A, Miaskowski C, Dodd MJ, Stotts NA, MacPhail L. Mechanisms for radiation-induced oral mucositis and the consequences. Cancer Nursing 2003;26:222-229 (Pubitemid 36622546)
4. Vissink A, Jansma J, Spijkervet FK, Burlage FR, Coppes RP. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:199-212. (Pubitemid 44560804)
5. Forastiere AA, Ang KK, Brizel D, et al. Head and neck cancers. J Natl Compr Canc Netw 2008;6:646-695
6. Allison RR, Vongtama V, Vaughan J, Shin KH. Symptomatic acute mucositis can be minimized or prophylaxed by the combination of sucralfate and fluconazole. Cancer Invest 1995;13:16-22.
7. Foote RL, Loprinzi CL, Frank AR, et al. Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 1994;12:2630-2633
8. Gordon B, Spadinger A, Hodges E, Ruby E, Stanley R, Coccia P. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 1994;12:1917-1922 (Pubitemid 24349395)
9. Crawford J, Tomita DK, Mazanet R, Glaspy J, Ozer H. Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. Cytokines Cell Mol Ther 1999;5:187-193 (Pubitemid 30330558)
10. Chi KH, Chen CH, Chan WK, et al. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 1995;13:2620-2628
11. Cartee L, Petros WP, Rosner GL, et al. Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 1995;7:471-477
12. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590-2598 (Pubitemid 39628580)
13. Verdi CJ, Garewal HS, Koenig LM, Vaughn B, Burkhead T. A doubleblind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:36-42.
14. Osaki T, Ueta E, Yoneda K, Hirota J, Yamamoto T. Prophylaxis of oral mucositis associated with chemoradiotherapy for oral carcinoma by Azelastine hydrochloride (Azelastine) with other antioxidants. Head Neck 1994;16:331-339 (Pubitemid 24188554)
15. Labar B, Mrsic M, Pavletic Z, et al. Prostaglandin E2 for prophylaxis of oral mucositis following BMT. Bone Marrow Transplant 1993;11: 379-382 (Pubitemid 23162502)
16. Shenep JL, Kalwinsky DK, Hutson PR, et al. Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapyinduced mucositis. J Pediatr 1988;113:758-763
17. Jebb SA, Osborne RJ, Maughan TS, et al. 5-Fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation. Br J Cancer 1994;70:732-735
18. Rocke LK, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. Cancer 1993;72:2234-2238
19. Cowen D, Tardieu C, Schubert M, et al. Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 1997;38:697-703. (Pubitemid 27310537)
20. Brizel DM, Murphy BA, Rosenthal DI, et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 2008;26:2489-2496
21. Campbell KC, Rybak LP, Meech RP, Hughes L. D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res 1996;102:90-98 (Pubitemid 26388984)
22. Reser D, Rho M, Dewan D, et al. L- and D-methionine provide equivalent long term protection against CDDP-induced ototoxicity in vivo, with partial in vitro and in vivo retention of antineoplastic activity. Neurotoxicology 1999;20:731-748
23. Vuyyuri SB, Hamstra DA, Khanna D, et al. Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res 2008;14:2161-2170 (Pubitemid 351551129)
24. Benevenga NJ. Toxicities of methionine and other amino acids. J Agric Food Chem 1974;22:2-9.
25. Kaji H, Niioka T, Kojima Y, Yoshida Y, Kawakami Y. Urinary 3-methylthiopropionate excretion and the effect of D- or L-methionine ingestion studied in healthy subjects. Res Commun Chem Pathol Pharmacol 1987;56:101-109 (Pubitemid 17066772)
26. Kies C, Fox H, Aprahamian S. Comparative value of L-, and D-methionine supplementation of an oat-based diet for humans. J Nutr 1975;105:809-814
27. Stegink LD, Bell EF, Filer LJ, Jr., Ziegler EE, Andersen DW, Seligson FH. Effects of equimolar doses of L-methionine, D-methionine and L-methionine-dl-sulfoxide on plasma and urinary amino acid levels in normal adult humans. J Nutr 1986;116:1185-1192
28. Blom HJ, Boers GH, van den Elzen JP, Gahl WA, Tangerman A. Transamination of methionine in humans. Clin Sci (Lond) 1989;76: 43-49
29. Walser M, Lund P, Ruderman NB, Coulter AW. Synthesis of essential amino acids from their á-keto analogues by perfused rat liver and muscle. J Clin Invest 1973;52:2865-2877
30. Stekol JA, Szaran J. Pathological effects of excessive methionine in the diet of growing rats. J Nutr 1962;77:81-90.
31. Friedman M. Chemistry, nutrition, and microbiology of D-amino acids. J Agric Food Chem 1999;47:3457-3479 (Pubitemid 29449456)
32. Crome P, Vale JA, Volans GN, Widdop B, Goulding R. Oral methionine in the treatment of severe paracetamol (Acetaminophen) overdose. Lancet 1976;2:829-830
33. Crome P, Vale JA, Volans GN, Widdop B, Goulding R. Methionine in treatment of acetaminophen poisoning. N Engl J Med 1977; 296:824.
34. Crome P, Volans GN, Vale JA, Widdop B, Goulding R. The use of methionine for acute paracetamol poisoning. J Int Med Res 1976;4:105-111
35. Monteagudo FS, Straughan JL, van der Merwe LP. The choice between intravenous N-acetylcysteine and oral methionine in paracetamol poisoning. S Afr Med J 1986;69:279.
36. Vale JA, Meredith TJ, Goulding R. Treatment of acetaminophen poisoning. The use of oral methionine. Arch Intern Med 1981;141:394-396
37. Delrieu F, Ferrand B, Amor B. Preliminary study of L-methionine in the treatment of rheumatoid polyarthritis [French]. Rev Rhum Mal Osteoartic 1988;55:995-997 (Pubitemid 19003560)
38. Di Rocco A, Tagliati M, Danisi F, Dorfman D, Moise J, Simpson DM. A pilot study of L-methionine for the treatment of AIDS-associated myelopathy. Neurology 1998;51:266-268 (Pubitemid 28345398)
39. Dorfman D, Di Rocco A, Simpson D, Tagliati M, Tanners L, Moise J. Oral methionine may improve neuropsychological function in patients with AIDS myelopathy: results of an open-label trial. AIDS 1997;11:1066-1067 (Pubitemid 27259538)
40. Di Rocco A, Werner P, Bottiglieri T, et al. Treatment of AIDS-associated myelopathy with L-methionine: a placebo-controlled study. Neurology 2004;63:1270-1275 (Pubitemid 39350029)
41. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-937 (Pubitemid 19249331)
42. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-1944
43. Seigel LJ, Longo DL. The control of chemotherapy-induced emesis. Ann Int Med 1981;95:352-359
44. Adelstein DJ, Saxton JP, Lavertu P, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1997;19:567-575 (Pubitemid 27407310)
45. Bairati I, Meyer F, Gelinas M, et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol 2005;23:5805-5813 (Pubitemid 46300177)
46. Bairati I, Meyer F, Jobin E, et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer 2006;119:2221-2224 (Pubitemid 44423684)